Know Cancer

forgot password

A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Phase 1
18 Years
Not Enrolling
Cutaneous T-cell Lymphoma

Thank you

Trial Information

A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Inclusion Criteria:

- Confirmed relapsed or refractory cutaneous T-cell lymphoma (CTCL):

1. Mycosis fungoides Stage IB or higher

2. Sézary syndrome

3. Primary cutaneous anaplastic large cell

- No curative treatment options.

- Progression of disease (PD) or relapse of disease after at least 1 previous systemic
therapy, PD after last prior treatment regimen, and recovered from the toxic effects
of prior therapy.

- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

- Life expectancy ≥ 3 months.

- Adequate blood, liver, and kidney function as determined by laboratory tests.

- Methylmalonic acide (MMA) serum concentration < 200 nmol/L and homocysteine (Hcy)
concentration < 10 μmol/L at screening, or receipt of 1 mg daily oral folic acid for
at least 10 days prior to the planned start of pralatrexate and 1 mg intramuscular
vitamin B12 within 10 weeks of the planned start of pralatrexate.

- Women of childbearing potential must use a medically acceptable contraceptive regimen
from study treatment initiation until at least 30 days after the last dose of
pralatrexate and must have a negative serum pregnancy test within 14 days prior to
the first day of study treatment. Serum pregnancy test not required for patients who
are postmenopausal (greater than 12 months since last menses) or are surgically

- Women who are breastfeeding.

- Men who are not surgically sterile must use a medically acceptable contraceptive
regimen from start of pralatrexate until at least 90 days after the last
administration of pralatrexate.

- Written informed consent and privacy authorization.

Exclusion Criteria:

- Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of
the cervix). If there is a history of prior malignancy, the patient must be
disease-free for ≥ 5 years. Patients with other prior malignancies < 5 years before
study entry may be enrolled if treatment resulted in complete resolution of the
cancer and currently have no clinical, radiologic, or laboratory evidence of active
or recurrent disease.

- Congestive heart failure Class III/IV per the New York Heart Association Heart
Failure Guidelines.

- Uncontrolled hypertension.

- Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of <100 mm3 or
detectable viral load within the past 3 months, and is receiving combination
anti-retroviral therapy.

- Symptomatic central nervous system metastases or lesions for which treatment is

- Active uncontrolled infection, underlying medical condition that would impair ability
to receive protocol treatment.

- Major surgery within 2 weeks of planned start of treatment.

- Receipt of any conventional chemotherapy or radiation therapy (RT) encompassing >10%
of bone marrow within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to
study treatment or planned use during the study.

- Receipt of systemic corticosteroids within 3 weeks of study treatment, unless on a
continuous dose of ≤10 mg/day of prednisone for at least 1 month.

- Initiation of or change in dosage of topical corticosteroids within 3 weeks of study
treatment (topical steroid use within 3 weeks is allowed if strength/use has been
stable for at least 1 month; topical corticosteroids cannot be started during the

- Use of investigational drugs, biologics, or devices within 4 weeks prior to study
treatment or planned use during the study.

- Receipt of a monoclonal antibody within 3 months without evidence of progression.

- Use of oral retinoids within 4 weeks of study treatment or high-dose vitamin A.

- Previous exposure to pralatrexate, unless the patient was on this study, achieved a
complete or partial response, and was taken off study treatment because of
investigator decision, and subsequently experienced disease recurrence or progressive

- Re-entering patients: must not have received subsequent therapy for CTCL during the
time off initial study treatment.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine an Effective and Well-tolerated Dose and Schedule of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma (CTCL)

Outcome Time Frame:

Assessed at the end of every even-numbered cycle (every 8 weeks) for the first 6 months, then every 4 cycles (16 weeks)

Safety Issue:


Principal Investigator

Michael Saunders, MD

Investigator Role:

Study Director

Investigator Affiliation:

Spectrum Pharmaceuticals, Inc


United States: Food and Drug Administration

Study ID:




Start Date:

August 2007

Completion Date:

February 2012

Related Keywords:

  • Cutaneous T-cell Lymphoma
  • Relapsed or Refractory Cutaneous T-cell Lymphoma
  • Lymphoma
  • Cutaneous T-cell Lymphoma
  • T-cell Lymphoma
  • Mycosis fungoides
  • Sézary syndrome
  • Primary cutaneous anaplastic large cell
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Washington University School of MedicineSaint Louis, Missouri  63110
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
City of Hope National Medical CenterLos Angeles, California  91010
Stanford University School of MedicineStanford, California  94305-5317
Emory UniversityAtlanta, Georgia  30322
University of Texas MD Anderson Cancer CenterHouston, Texas  77030
Fred Hutchinson Cancer CenterSeattle, Washington  98109
Yale University School Of MedicineNew Haven, Connecticut  06520
Columbia University Medical CenterNew York, New York  10032